

Natural transmission of USP9Y gene mutations: a new perspective on the role of AZFa genes in male fertility

Csilla Krausz^{1,*}, Selene Degl'Innocenti¹, Francesca Nuti¹, Annamaria Morelli¹, Federica Felici¹, Mauro Sansone², Gennaro Varriale³ and Gianni Forti¹

¹Andrology Unit, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy, ²U.O.C. di Molecular Genomics and Biochemistry ASL n.1 Naples, Italy and ³Department of Molecular and Cellular Pathology 'Federico II' Via S. Pansini, 5, Naples, Italy

Received April 10, 2006; Revised July 19, 2006; Accepted July 27, 2006

Deletions of the azoospermia factor (AZF) regions of the Y chromosome are associated with severe spermatogenic failure and represent the most frequent molecular genetic cause of azoospermia and severe oligozoospermia. The exact role of the candidate AZF genes is largely unknown due to both the extreme rarity of naturally occurring AZF gene-specific mutations and the lack of functional assays. Here, we report the fine characterization of two different deletions in the *USP9Y* gene (one of the two candidate genes in the AZFa region), which have been transmitted through natural conception in two unrelated families. The associated mild testicular phenotype, in both cases, is in sharp contrast with that of the two previously reported infertile patients bearing a mutation of the same gene. In conclusion, to date, the *USP9Y* gene has been considered as one of the major Y-linked spermatogenesis genes, based on both its position within the AZFa region and previous reports that correlated *USP9Y* mutation to severe spermatogenic failure and infertility. This view is now substantially changed because our findings clearly demonstrate that during human spermatogenesis, *USP9Y* is more likely a fine tuner that improves efficiency, rather than a provider of an essential function. More importantly, the observed natural conceptions suggest that the protein is not required for the final sperm maturation process or for the acquisition of sperm fertilizing ability, providing a new perspective on the role played by the *USP9Y* gene in male fertility.

INTRODUCTION

The long arm of the human Y chromosome hosts a number of genes involved in spermatogenesis and several types of recurrent Yq deletions are firmly associated with spermatogenic failure (reviewed in 1–3 and references therein). However, because each of these deletions removes multiple genes, such observations do not allow attribution of spermatogenic function to any particular Y chromosome encoded protein. Despite the efforts of many laboratories, only two cases of confirmed isolated Yq gene mutation have been reported to date (4,5).

The rarity of single azoospermia factor (AZF) gene mutations or deletions is in sharp contrast with the relatively high frequency of AZF deletions [classically divided into

three AZF regions, AZFa, AZFb and AZFc (6)], which represent the most frequent molecular genetic cause of azoospermia and severe oligozoospermia (<5 millions spermatozoa/ml) (reviewed in 2 and references therein). A likely explanation is that the peculiar structure and the sequence organization of the Y chromosome make this chromosome prone to the loss of large regions, such as the AZF regions.

AZFa deletion is relatively rare (less than 2% of Yq deletions observed in men tested because of low sperm count), and in all known cases, it causes complete absence of germ cells [Sertoli cell only syndrome (SCOS)] (7). AZFa region contains two widely expressed genes, *USP9Y* and *DDX3Y* (previously called *DBY*) (3,8). *USP9Y* is the only Yq gene for which isolated mutations have been reported: a massive deletion removing entirety of *USP9Y* and a 4 bp splice-donor

*To whom correspondence should be addressed. Tel: +39 0554271485; Fax: +39 0554271371; Email: c.krausz@dfc.unifi.it

site deletion resulting in severely truncated protein (4,5). In the first case, the outcome was severe oligospermia (3 millions spermatozoa/ml), whereas the second case resulted in azoospermia. In both patients, testicular histology showed hypospermatogenesis with occasional tubules containing only premeiotic or meiotic germ cells (spermatogenic arrest). These findings lead to the conclusion that although complete absence or significant truncation of *USP9Y* protein is not enough to produce the full AZFa phenotype, it still causes azoospermia or severe oligozoospermia and infertility. We report two unique cases of deletions removing part of the *USP9Y* gene which were spontaneously transmitted. In one family, the transmission has occurred through two generations and represents the first description of a familial case of partial AZFa deletion. The second deletion was naturally transmitted from a sub-fertile father to his son while the couple was on the waiting list for assisted reproductive techniques. The observed phenotypes provide important new insights into the role of AZFa genes in male fertility.

RESULTS

Our attention was focused on two patients (1115/0 and A333) of a large series of 995 subjects affected by infertility because of the presence of deletions removing part of the *USP9Y* gene. The frequency for isolated *USP9Y* gene-specific deletion in this cohort is 0.2%, which confirms the rarity of these types of deletions in the Y chromosome. In addition, 350 normospermic men were screened for gene-specific deletions, with no observed deletions for either of the two *USP9Y* markers.

Fine characterization of the deletions

In order to establish the exact extension and the mechanism of formation of the deletions, we performed a fine mapping with an additional set of markers, as reported in Tables 1 and 2.

Patient 1115/0 showed an intact Y chromosome following the routine analysis, although gene-specific screening showed the absence of exon 46 of *USP9Y* (with exon 22 present) (Fig. 1). We used a number of additional gene-specific markers (Table 1) to localize the breakpoints to intervals less than 1 kb. After fine mapping of the deletion breakpoints, we used long-range PCR to amplify and sequence the breakpoints (Fig. 2A). The deletion removes 31925 bp with a proximal breakpoint in *USP9Y* intron 33, whereas the distal breakpoint is located 2366 bp downstream of the last *USP9Y* exon (GenBank accession no. DQ665365).

Patient A333 showed a deletion of the AZFa markers which are routinely used: sY86 and sY84. The gene-specific screening revealed the absence of exon 22 but the presence of exon 46 of *USP9Y*. We used a number of additional gene-specific markers (Table 2) to localize the breakpoints to intervals <1.5 kb. After fine mapping of the deletion breakpoints, we used long-range PCR to amplify and then sequence the breakpoints, as shown in Figure 2B. The deletion removes 389 404 bp with a proximal breakpoint 280 775 bp before the first exon of *USP9Y*, whereas the distal breakpoint is located in intron 28 of the *USP9Y* gene (GenBank accession no. DQ665366).

The alignment of the flanking sequences (Fig. 2A and B) shows that neither of these deletions is caused by ectopic homologous recombination. This contrasts with the vast majority of Y chromosomal deletions reported to date, which appear to be caused by ectopic homologous recombination between direct repeats (3,9–12 and references therein).

Analysis of DNA from ejaculated spermatozoa

As it was not known whether the father of patient A333 had the deletion, it was necessary to consider mosaicism as a possible explanation for the mild spermatogenic phenotype. In order to rule out the presence of a mixed population of germ cells with a proportion carrying an intact Y chromosome, DNA was extracted from ejaculated spermatozoa of patient A333. Sperm-derived DNA showed the same deletion pattern as the genomic DNA (no amplification for sY84, sY86 and exon 22 of *USP9Y*) indicating that all spermatozoa were derived from germ cells carrying the *USP9Y* deletion.

Gene expression analysis

As both patients presented spermatozoa in their ejaculate, testis biopsy was not medically indicated and we were unable to carry out testicular expression analysis.

Patient 1115/0. As the first 33 exons have been retained and the distal breakpoint of the deletion falls between *USP9Y*, which is partially deleted, and *DDX3Y*, which is retained, we sought to verify the effect of the deletion on the expression of both genes. RT-PCR revealed the presence of the 5' end of *USP9Y* transcript and, as expected, the absence of its 3' end, suggesting the translation of a truncated protein (Fig. 3A).

While performing the RT-PCR of the 5' end, we noticed the presence of a strong band that migrated lower than expected. The sequencing of this product showed a 60 bp deletion in the 5'-UTR, where the first two non-transcribed exons are located (Fig. 3C). These data indicate an alternative splicing of the transcript, removing exon 2 from the gene product (GenBank accession no. DQ151535). We found the same alternatively spliced product in the mRNA originated from the control testis and from two control men without Y deletion (Fig. 3B). This alternatively spliced mRNA which appears to be the major transcript in both leucocytes and testes was not reported previously and its functional role is yet to be established.

Because the position of the *DDX3Y* upstream regulatory elements is unknown, we sought to verify *DDX3Y* transcription, which may be affected by position effect silencing due to the deletion. We ruled out this possibility after having performed an RT-PCR analysis, which confirmed the presence of both 5' and 3' *DDX3Y* transcripts in the patient's lymphocytes (Fig. 3A). In addition, in order to rule out a possible quantitative effect of the *USP9Y* deletion on *DDX3Y* expression, we performed real-time PCR assay for *DDX3Y*. We did not observe relevant differences in the expression of the *DDX3Y* gene between patient 1115 and the two control men (normozoospermic/fertile without Y deletions) (data not shown).

Patient A333. Although we were unable to carry expression analysis in this patient, it is highly unlikely that the undeleted

Table 1. Primers for PCR amplification used for the fine mapping of the breakpoints in patient 1115/0

USTS	Segment amplified	Fragment length (bp)	Primers (5'→3')	
			Forward	Reverse
1	Exon 22	204	ttttagcacaattgcagg	ttctgtggaataggggatg
2	Exon 25	264	ggfagtgatgaggagtaaaaa	cattcaagatcccagaactgtc
3	Exon 27	430	ggagtacctatcactgaatgtgc	gtcattctttctcttggaaac
4	Intron 33	401	gtattccctttgaagaacatattg	aagtcacacaaagtaattttt
5	Intron 33	413	ttgcaagatgctattgctgg	gccacctacctcccttacc
6	Intron 33	370	catgcaagaagcaggaaca	attacaagcatgaccacca
7	Intron 33	222	tcactggctgtgggacaac	ccgtgcatctaacaccagaa
8	Intron 33	215	ggggtgtgtatgtgtgtg	gcattgcttgggaaaaa
9	Intron 33	218	gtgaacctcaactgtgect	ttccatgctatgcctttt
10	Intron 33	216	gctgttcccagcaattt ^a	cttgacatcttctgacgg
11	Intron 33	374	catggatcmetaattccaca	acagcgtgtgtataagtggg
12	Exon 34	472	aacgggaaacctttcactt	taacaggttaccaccaagc
13	Intron 34	292	tctctatgggtgtgtctctg	gctgggattacagaagctg
14	Exon 42	447	tgaccatcaactgacac	ccattgaccaaactgatcc
15	Exon 46	111	gagccatctttgtcagtttac	ctgcaattttccacataacc
16	Post-USP9Y	260	attgccatgcaaaagttagc	tgctgctctgagactgaa ^a
17	Post-USP9Y	151	ttgtgtgagcattccaaa	aggcaggggaagagatgagt
18	Post-USP9Y	201	aactgcatcaagcccaaatc	agtgtcagcattcttcca
19	Post-USP9Y	209	gagaccagcatgggaaacat	gctttccaacctctcca
20	Post-USP9Y	280	ctggatcacagtgcattgg	aagaaaaagggccctaaat
21	Post-USP9Y	349	ttgctaagataggggctctt	caatatgttgagacccccac
22	Post-USP9Y	233	ggagacagaatgccaaggac	ggggagggagaggtatattg
23	Post-USP9Y	429	ttgattgcatcccttaggc	ttggctcatgcttaaatg

^aPrimer sequences used for junction amplification.

3' portion of USP9Y was transcribed, because the deletion removed 28 kb of sequence upstream of the normal position of the first exon.

Y chromosome analysis in male relatives

Our next step was to evaluate whether the deletion in patient 1115/0 occurred *de novo*. Patient's father had died, but we were able to obtain blood from two of his brothers and from three of their male offspring. All male relatives lacked exon 46 of the USP9Y gene (Fig. 4A), and the same junction sequence was successfully amplified with deletion-specific primers (data not shown). The deletion therefore has been transmitted from the father of the proband to three sons without medical intervention. His age at the time of conception of the first and last sons was 36 and 43, respectively. The two brothers of the proband also induced spontaneous pregnancies (one of them had two sons, the other had one son), whereas the third cycle of *in vitro* fertilization was successful for the 35-year-old proband 1115/0 (Fig. 4B). A healthy baby girl was delivered a few months ago.

In order to verify the paternity and an eventual further expansion of the deletion in patient A333, we analysed the DNA of the son and found that the deletion was inherited unchanged. In the same way, no further expansion of the deletion was observed in the sons of the brothers of proband 1115/0.

DISCUSSION

The AZFa region contains two genes, namely DDX3Y (former *DBY*) and USP9Y, and the removal of both genes is associated

with the complete absence of spermatogenic cells in the testis. To date, only two infertile patients with confirmed deletions inside or removing the whole USP9Y gene (4,5) have been reported, and no cases of confirmed isolated DDX3Y deletions have been published. A critical role only for DDX3Y [predominantly expressed in spermatogonia (13)] in the AZFa deletion phenotype has been proposed on the basis of residual spermatogenesis in the testis of the two patients with USP9Y mutation. However, a formal demonstration to support this hypothesis is still lacking and the question about the exact phase(s) of the spermatogenic process in which each of these genes is participating needs to be clarified.

Our study provides new insights into the function of the USP9Y gene. The natural transmission of deletions involving the USP9Y gene suggests that the absence of the USP9Y gene product does not preclude sperm-fertilizing ability and thus it is not critical for the final sperm maturation process, i.e. spermiogenesis. This observation radically changes our view on the putative role of this protein, because the predicted function of the USP9Y protein, as a deubiquitinating enzyme involved in protein stability control, is expected to be relevant in the late phases of spermatogenesis when active transcription ceases (14). The recent observation of a likely non-functional USP9Y gene product in the chimpanzee is intriguing, raising questions about an essential role of this gene in primate's spermatogenesis (15). However, the presence of moderate oligoasthenoteratozoospermia in both of our patients, and the severe impairment of spermatogenesis in the two previously reported cases, would predict a conserved (although probably marginal) functional role for this gene in humans. The unaffected expression level of the downstream DDX3Y gene clearly demonstrate that the observed phenotypes are the consequence of the USP9Y gene deletion.

Table 2. Primers for PCR amplification used for the fine mapping of the breakpoints in patient A333

STS	Segment amplified	Fragment length (bp)	Primers (5'→3')	
			Forward	Reverse
P-1	Anonymus	494	tttggctcgggacacaagt	caccgcagttctgcage
P-2	Anonymus	587	tcttgaacagcatcgtggg	tgcccacctcatctccc
P-3	Anonymus	702	ccgccctccttttcattg	tgaacttggttggcagagat
P-4	Anonymus	184	ccagatcaagttatttaggagagca	tatgaatgggacgaggagg
P-5	Anonymus	250	gaggaggatctcagggttctaag	tctgtggtatcagtcagtgatca
P-6	Anonymus	374	gcaacctgaactggagccct	ccacaagaaagatgctggct
P-7	Anonymus	168	ctgccattctgccattc ^a	agccccaggagtcaaggtg
P-8	Anonymus	321	ggaaactggtgagaacccaa ^a	cgaggatttattccacca
P-9	Anonymus	183	gcacttcttgagtactgga	actggagtacggggggg
P-10	Anonymus	202	ctctcagctctacgtcccc	aggtcagagagaggtgccc
P-11	Anonymus	256	aggcctcctccactgcat	ggttctcctcctctcct
P-12	Anonymus	226	aaactgcacgcatgaatga	cgaaaatggtgagtcactgg
P-13	Anonymus	411	gaaagagagcttgcccag	tggcattcacctattcccac
P-14	Anonymus	443	aaattaagaccggagcggc	ataaaacgcatttggccatc
D-1	USP9Y intron 24	264	ggtgatggatgaggagtaaaaa	cattcaagatcccagactgtc
D-2	USP9Y intron 26	430	ggagtacatcactgaatgtgc	gtcattcattctgcttggaac
D-3	USP9Y intron 27	226	tgtattcgttttgcctgaa	caaggaccagagtgttcaact
D-4	USP9Y intron 27	603	gatctgggctcttctcca	ttcccagagtttgagggtg
D-5	USP9Y intron 27	268	cagtcacaagctcctcctga	caataggtgcagttggcaga
D-6	USP9Y intron 27	208	tattcctcccgtgtgaagc	catggtggctcatgcat
D-7	USP9Y intron 27	438	tgctcagccttcagtttt	atttcaatgtgagccctg
D-8	USP9Y intron 27	334	accttgacatgatccacc	gaactgctcctgtgccaact
D-9	USP9Y Exon 28	544	ccatactgggggtgagaagt	accctaactcctttcagcca
D-10	USP9Y intron 28	363	gggaaaaatacactacgtcttg	accctaactcctttcagcca ^a
D-11	USP9Y intron 28	202	tggactctgagtgactgtga	accctaactcctttcagcca
D-12	USP9Y Exon 29	153	tgattattcacactttacggc	accctaactcctttcagcca
D-13	USP9Y intron 29	117	aacctccttctcctgtggt	ttgacacctgttcacctg
D-14	USP9Y intron 30	261	gcaccagcctcttaaggt	tctctaaagtgaggcacact
D-15	USP9Y intron 30	401	gtattcctttgaagaacatattg	aagtcacacaaagtaattttt

^aPrimer sequences used for junction amplification.

DNA analysis of the male relatives was performed for only one of the two previously reported carriers of USP9Y deletion/mutation. In patient WHT2780, the *de novo* nature of the intra-genic mutation has been confirmed (5). This patient was affected by azoospermia, which by definition precludes spontaneous conception. It is clear that in both of our patients, and in the 1115/0 patient's relatives, the consequences of the USP9Y loss are much less severe than in the previously reported cases and are compatible with natural fertility. The subfertility of patient 1115/0 is in contrast with the natural fertility of his father and brother, but can be explained by the well-known concept that fertility is not a synonym of normozoospermia; therefore, the fertility of a couple depends on the fertility status of both partners. The spontaneous pregnancies achieved in couple A333 and in the father and brothers of patient 1115/0 are typical examples for the potential compensation of a highly fertile female partner for mild male factor.

How can the loss of the same gene (or part of it) be associated with such different spermatogenic phenotypes in unrelated subjects? The deletion in the 1115 family leads to the expression of a truncated protein, which might have preserved some residual functional competence and it may explain the milder phenotype. However, the structural analysis of the truncated protein predicts a different scenario. The *USP9Y* gene contains two highly conserved functional domains (Cys and His domains, respectively), which are almost identical to those found in mouse (*Usp9x* previously called *Dffrx*) and on the human X chromosome (*USPX*) homologues (4). The

deletion in the 1115 family has removed almost the entire peptidase unit, including the His domain, whereas the Cys domain remained intact. It is therefore unlikely that the truncated protein has maintained a full biological function.

More importantly, a similar mild phenotype was found also in patient A333 in which the *USP9Y* gene product is completely lacking due to the removal of the promoter region. This observation clearly rules out a possible residual functional competence as an explanation for the observed phenotypic differences.

The widely heterogeneous phenotype can be related to the different genetic background of the four individuals. For example, the factor influencing the testis phenotype can be a variation in the degree to which the X homologue *USP9X* complements or compensates for absent or diminished *USP9Y* function. It is also possible that the severe phenotype in the two previously reported cases was related to the presence of other co-factors (including environmental or genetic factors) or other pathological conditions affecting testis function. As the phenotypic description of these cases is focused only on sperm analysis and the testicular histology, these hypotheses cannot be ruled out.

The effect of the mutation on spermatogenesis may also depend on other Y chromosome genes, and we have defined the patient's Y haplotype for future comparisons. Using six biallelic markers (SRY1532, M9, 92R7, YAP, 12f2, LLY22g), which are known to be polymorphic in the European populations (16), we assigned patient's Y chromosome




Figure 1. Intragenic deletion of the *USP9Y* gene in patient 1115/0 and A333. PCR amplifications with the standard AZFa markers are shown on the right side of the figure. Schematic representation of the Y chromosome, including the three AZF regions. STS markers used for the routine screening and the two *AZF*a genes (*USP9Y* and *DDX3Y*) with their exon/intron structure are shown and reported to scale. Coding exons in black. The extent of the deletions are shown as a gap (shown to scale).

to haplogroup Hgr2 (Y* (xD,E,J,N,P) non-derived for patient 1115/0 and Hgr12 (hgr N) for patient A333. Unfortunately, Y chromosome haplogroups of the previously described two patients were not defined. Therefore, we could not compare the Y backgrounds.

Apart from the moderate/mild oligoasthenoteratozoospermia, the two patients and their relatives were healthy. This is noteworthy because both *USP9X* and *USP9Y* are expressed throughout the body. It is therefore likely that a double dosage provided by the two homologous genes is required only for germ cell development. It would be important, although difficult to perform, a genome-wide gene expression profiling in these individuals in order to get further insights into the effect of a reduced gene dosage in organs other than the testis.

Moreover, our finding raises questions about the appropriateness of the currently used routine Y chromosome analysis (17). On the basis of routine protocol, patient 1115/0 should have been missed because the two routine markers (sY84 and sY86) mapping outside of the AZFa genes were present. However, the rarity of isolated *USP9Y* deletions in our study population and the absence of confirmed *USP9Y*-specific deletions (apart from cases WHT2780 and Sayer) in the literature make questionable its cost-effectiveness in a routine diagnostic setting. However, the low frequency of *USP9Y* gene-specific deletions may also be related to the type of patients who are routinely tested for Y deletions, i.e. severe oligospermic or azoospermic men. Nevertheless, the analysis of the breakpoints of the intragenic deletion in the 1115 family did not reveal a potential hot spot for deletion formation which makes unlikely the recurrence of this specific event in other infertile men.

On the contrary, case A333 underlies the importance of the definition of the extension of AZF deletions ('partial' or 'complete') and thus the need for a second step analysis (18). For

this purpose, we would suggest performing a gene-specific approach using the same or similar set of markers for the two AZFa genes.


In conclusion, up to now the *USP9Y* gene was considered as one of the major Y-linked spermatogenesis genes, both for its position (AZFa region) and the previously reported genotype–phenotype correlation (infertility due to severe spermatogenic failure). This view is now substantially changed because our findings clearly indicate that the protein is not required for the acquisition of sperm-fertilizing ability. During human spermatogenesis, its role is more likely a fine-tuner that improves efficiency, rather than a provider of an essential function.

MATERIALS AND METHODS

Subjects


After the routine analysis (discussed subsequently), 995 subjects were identified without classical, or 'complete', AZF deletions. The inclusion criteria of patients were based on reduced or absent sperm counts and the lack of karyotype anomalies. Eighty percent of patients were referred because of a sperm concentration below 5 millions/ml, whereas the remaining were in the mild or moderate oligospermic range (5–20 millions spermatozoa/ml). Forty percent of patients were defined as 'idiopathic' because of the absence of known causes of spermatogenic disturbances. A total of 350 normospermic men were screened for AZF deletions and *USP9Y* gene-specific deletions. Normospermia is characterized by the following sperm parameters: sperm concentration >20 millions spermatozoa/ml; total sperm number/ejaculate >40 millions spermatozoa; progressive sperm motility

A



Proximal sequence **CAGTGAATACAGAACAGAAAGAACTGCCCTCAGCTTAATAAAAGCCAT**GTATAAAAACTCTGAGCAAGCATATTTGTAATATAAGCT
 # 1115 sequence **CAGTGAATACAGAACAGAAAGAACTGCCCTCAGCTTAATAAAAGCCATT**CAGATTGTGGATCATAACGCCCAAAATATTGAGAGAGAG
 Distal sequence **TTTAACCATAGTTTCAGTCTGCCTAATAACCTGCAAGCACTTCCAAAATCAGATTGTGGATCATAACGCCCAAAATATTGAGAGAGAG**

B



Proximal sequence **GAACAGGCAGGCTGAACCTGAAGGAGCTTGAGCTACTCACCCGACATGGT**CGTGGCGCCGACGCAGTGGCGCGGACCCGCAGACCTGCGCCAGGCGCA
 A333 **GAACAGGCAGGCTGAACCTGAAGGAGCTTGAGCTACTCACCCGACATGGTCTTTTAAATGTGCACCAGATGTTGCATGGGACACAGGCCTCTGCTTTTCTTC**
 Distal sequence **CATTTTGTTTTATTTTCAGAAGTTCCTGTCAGTTGGCAGCAGGAGCAGTCTCTTTTAAATGTGCACCAGATGTTGCATGGGACACAGGCCTCTGCTTTTCTTC**

Figure 2. Fine mapping of the deletion breakpoint. Additional markers with their GenBank position used to narrow down the deletion gap. (A) The final long-range PCR product gave a band of about 800 bp in patient 1115/0, whereas no amplification was obtained in male and female controls. The chromatogram of the sequence containing the breakpoints is shown. (B) the final long-range PCR product gave a band of about 1400 bp in patient A333, whereas no amplification was obtained in male and female controls. The chromatogram of the sequence containing the breakpoints is shown. Alignment of the sequences flanking the breakpoints is shown in the lower panel of each fine mapping scheme.




Figure 3. Expression analysis of the two *AZFa* genes performed in patient 1115/ (lymphocytes). (A) RT-PCR amplification using primers mapping into the 5' and 3' end of the two genes. No amplification of the 3' end of the *USP9Y* gene was observed, whereas the 5' end gave two bands. (B) RT-PCR amplification of the 5' of the *USP9Y* gene in lymphocytes (C1) and in testis biopsy (C2) of a control non-deleted man. (C) Direct sequencing of the smaller RT-PCR (asterisk) product confirmed that the untranslated exon 2 was not present.

type (a) > 25% or type (a + b) > 50% and morphology > 30% (19).

We report the Y chromosome analysis and the subsequent fine mapping of deletions in two unrelated subjects and in their family members: (i) patient 1115/0, of Italian origin, and his two brothers and three nephews and (ii) patient A333, from Romania, and his son.

Probands

Patient 1115/0. A 34 years old man seeking genetic analysis for infertility. The patient presented with moderate oligoastheno-teratozoospermia [sperm concentration 14 million spermatozoa/ml; total progressive motility (type a + b): 15%; percentage normal forms: 20%] an uneventful medical history and normal genitalia (bilateral testis volume: 15 ml). The patient had a normal male karyotype (46,XY).

Patient A333. A 32 years old man seeking genetic analysis for couple infertility with a history of a spontaneous abortion (between the fourth and fifth week of pregnancy) 2 years

earlier. The patient underwent several sperm analyses and presented a sperm count ranging from a minimum of 1.4 million spermatozoa/ml in September 2002 to 18 million spermatozoa/ml in December 2003. The total progressive motility (type a + b) varied from 2 to 18%, whereas the percentage of normal forms varied from 1 to 4%. The patient had an uneventful history and normal genitalia (bilateral testis volume: 20 ml). Both partners had a normal karyotype (46,XY and 46,XX).

Family of patient 1115/0

The patient's father had died. His age at the time of conception of three sons was 36, 37 and 43 years. We collected DNA from all male family members. The two brothers 1115/1 and 1115/2 (39 and 40 years old, respectively, at the time of the study) were able to spontaneously conceive children. Subject 1115/1 has two sons (1115/3 and 1115/4) conceived when he was 36 and 38 years old, whereas subject 1115/2 has one son (1115/5) conceived at the age of 37.




Figure 4. (A) PCR amplification of gene specific markers mapping to exons 22 and 46 of the *USP9Y* gene. The expected size of the PCR products is indicated with the narrow (in the normal male control). Patient (1115/0) and his five male relative's codes (from 1115/1 to 1115/5) are indicated over the PCR products. All subjects show the lack of the exon 46 product. (B) The pedigree of the family is shown in the box.

The son of patient A333

Patient A333 has naturally conceived (after 3 years from the last pregnancy which ended with early abortion) a son who was 9 months old when came under observation. The baby presented normal male phenotype.

Informed consent to the molecular studies was obtained in all family members.

Methods

Molecular analysis. Genomic DNA was extracted from leucocytes using the standardized phenol–chloroform technique. In patient A333, DNA was also extracted from ejaculated spermatozoa. Routine Y chromosome microdeletion screening was performed according to the European Academy of Andrology/EMQN Guidelines (17), which includes six STS mapping into the three AZF regions and a pair of additional gene-specific markers from the short arm of the Yp (SRY and ZFX/ZFY). Patients presenting a deletion with the routine panel were further analysed with specific markers in order to define the type of deletion, i.e. complete or partial (17,18). In patients presenting with an intact Y chromosome from routine analysis, we performed a gene-specific PCR-based screening including the following Yq genes: *USP9Y* and *DDX3Y* (GenBank accession no. G49468) for the AZFa region and *HSFY* (GenBank accession no. G6635) and *eIF-1AY* (GenBank accession no. G29945) for the AZFb region. Because *USP9Y* is composed of 46 exons distributed across 159 kb of genomic DNA, we use two primer pairs, one mapping to exon 22 (GenBank accession no. G54725) and another to exon 46 (GenBank accession no. G34983).

We used a number of additional gene-specific markers (Tables 1 and 2) to localize the breakpoints to intervals

<1 kb in patient 1115/0 and 1.5 kb in patient A333. The deletion junction has been then amplified using long-range PCR, and the amplified products were sequenced by automatic sequencer (ABI PRISM 310, Applied Biosystems, Foster City, CA, USA). The primers used for the long-range PCR are indicated in the tables with ^(A).

Gene expression analysis in patient 1115/0. Total RNA has been extracted from the patient's lymphocytes using TRIZOL reagent (Invitrogen Corporation, Carlsbad, CA, USA) and from the control's frozen testicular tissue using a commercially available RNAeasy mini kit (Quiagen Inc. Valencia, CA, USA). Testis tissue from man with normal spermatogenesis (obstructive azoospermia) was used as a control. RNA integrity was assessed by electrophoresis in agarose gel. For each sample, an amount of total RNA corresponding to 1 µg was reverse transcribed to cDNA in a final volume of 80 µl using TAqMan Reverse Transcription kit (Applied Biosystems) at the following conditions: 10 min at 25°C, 30 min at 48°C and 5 min at 95°C.

The sequences of the primer used for the detection of the 3' and 5' ends of the *USP9Y* and *DDX3Y* mRNA were the following:

USP9Y 5' for TGTTTTGCAGAGAGCTTGGG (exon 1)
USP9Y 5' rev GCTGTCGTTCCCTCCTACTG (exon 3)
USP9Y 3' for ATCCTCATTACCTGCCTCT (exon 45)
USP9Y 3' rev ACTCCATGTTGGTTGGAGC (exon 46)
DDX3Y 5' for ATTGGCAATCGTGAAAGACC (exon 5)
DDX3Y 5' rev TTAAGTCCGTTGCTCTAC (exon 6)
DDX3Y 3' for GTTCCGGCTTTGGTGCTAGT (exon 16)
DDX3Y 3' rev GAGCTCCCTTGAATTATCAGGA (exon 17)

ACKNOWLEDGEMENTS

This study was supported by grants from the University of Florence and a grant PRIN from MIUR (responsible for the Florence Unit: C.K.). We thank Helen Skaletsky for her precious advises during the experimental work and for her comments on the manuscript. We thank also David Page, Steve Rozen, Paolo Tomasi, Paolo Sassone-Corsi, Mike Mitchell and Doug Carrell for helpful discussions on the manuscript.

Conflict of Interest statement. None declared.

REFERENCES

- McElreavey, K. and Krausz, C. (1999) Sex chromosome genetics '99. Male infertility and the Y chromosome. *Am. J. Hum. Genet.*, **64**, 928–933.
- Krausz, C., Forti, G. and McElreavey, K. (2003) The Y chromosome and male fertility and infertility. *Int. J. Androl.*, **26**, 70–75.
- Skaletsky, H., Kuroda-Kawaguchi, T., Minx, P.J., Cordum, H.S., Hillier, L., Brown, L.G., Repping, S., Pyntikova, T., Ali, J., Bieri, T. *et al.* (2003) The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. *Nature*, **423**, 825–837.
- Brown, G.M., Furlong, R.A., Sargent, C.A., Erickson, R.P., Longepied, G., Mitchell, M., Jones, M.H., Hargreave, T.B., Cooke, H.J. and Affara, N.A. (1998) Characterisation of the coding sequence and fine mapping of the human *DFFRY* gene and comparative expression analysis and mapping to the Sxrb interval of the mouse Y chromosome of the *Dffry* gene. *Hum. Mol. Genet.*, **7**, 97–107.

5. Sun, C., Skaletsky, H., Birren, B., Devon, K., Tang, Z., Silber, S., Oates, R. and Page, D.C. (1999) An azoospermic man with a *de novo* point mutation in the Y-chromosomal gene *USP9Y*. *Nat. Genet.*, **23**, 429–432.
6. Vogt, P.H., Edelmann, A., Kirsch, S., Henegariu, O., Hirschmann, P., Kiesewetter, F., Kohn, F.M., Schill, W.B., Farah, S., Ramos, C. *et al.* (1996) Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. *Hum. Mol. Genet.*, **5**, 933–943.
7. Kamp, C., Huellen, K., Fernandes, S., Sousa, M., Schlegel, P.N., Mielnik, A., Kleiman, S., Yavetz, H., Krause, W., Kupker, W. *et al.* (2001) High deletion frequency of the complete AZFa sequence in men with Sertoli-cell-only syndrome. *Mol. Hum. Reprod.*, **7**, 987–994.
8. Sargent, C.A., Boucher, C.A., Kirsch, S., Brown, G., Weiss, B., Trundley, A., Burgoyne, P., Saut, N., Durand, C., Levy, N. *et al.* (1999) The critical region of overlap defining the AZFa male infertility interval of proximal Yq contains three transcribed sequences. *J. Med. Genet.*, **36**, 670–677.
9. Kamp, C., Hirschmann, P., Voss, H., Huellen, K. and Vogt, P.H. (2000) Two long homologous retroviral sequence blocks in proximal Yq11 cause AZFa microdeletions as a result of intrachromosomal recombination events. *Hum. Mol. Genet.*, **9**, 2563–2572.
10. Sun, C., Skaletsky, H., Rozen, S., Gromoll, J., Nieschlag, E., Oates, R. and Page, D.C. (2000) Deletion of azoospermia factor a (AZFa) region of human Y chromosome caused by recombination between HERV15 proviruses. *Hum. Mol. Genet.*, **9**, 2291–2296.
11. Kuroda-Kawaguchi, T., Skaletsky, H., Brown, L.G., Minx, P.J., Cordum, H.S., Waterston, R.H., Wilson, R.K., Silber, S., Oates, R., Rozen, S. *et al.* (2001) The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men. *Nat. Genet.*, **29**, 279–286.
12. Repping, S., Skaletsky, H., Lange, J., Silber, S., Van Der Veen, F., Oates, R.D., Page, D.C. and Rozen, S. (2002) Recombination between palindromes P5 and P1 on the human Y chromosome causes massive deletions and spermatogenic failure. *Am. J. Hum. Genet.*, **71**, 906–922.
13. Ditton, H.J., Zimmer, J., Kamp, C., Rajpert-De Meyts, E. and Vogt, P.H. (2004) The AZFa gene *DBY* (*DDX3Y*) is widely transcribed but the protein is limited to the male germ cells by translation control. *Hum. Mol. Genet.*, **13**, 2333–2341.
14. Sassone-Corsi, P. (2002) Unique chromatin remodeling and transcriptional regulation in spermatogenesis. *Science*, **296**, 2176–2178.
15. Hughes, J.F., Skaletsky, H., Pyntikova, T., Minx, P.J., Graves, T., Rozen, S., Wilson, R.K. and Page, D.C. (2005) Conservation of Y-linked genes during human evolution revealed by comparative sequencing in chimpanzee. *Nature*, **437**, 100–103.
16. Rosser, Z.H., Zerjal, T., Hurles, M.E., Adojaan, M., Alavantic, D., Amorim, A., Amos, W., Armenteros, M., Arroyo, E., Barbujani, G. *et al.* (2000) Y-chromosomal diversity in Europe is clinal and influenced primarily by geography, rather than by language. *Am. J. Hum. Genet.*, **67**, 1526–1543.
17. Simoni, M., Bakker, E. and Krausz, C. (2004) EMQN best practice guidelines for molecular diagnosis of y-chromosomal, microdeletions. State of the art 2004. *Int. J. Androl.*, **27**, 240–249.
18. Krausz, C. and Degl'Innocenti, S. (2006) Y chromosome and male infertility: update, 2006. *Front. Biosci.*, **11**, 3049–3061.
19. World Health Organization. (1999) *WHO Laboratory Manual for the Examination of Human Semen and Sperm–Cervical Mucus Interaction*, 3rd edn. Cambridge University Press, Cambridge, UK, pp. 4–33.